Organisation paid for research Program year 2025 Source: CMS Open Payments

UPMC

Neither a doctor nor a teaching hospital

Research payments

$5,081,936

302 payments

Through program year 2025, UPMC is reported as receiving $5,081,936 in research payments, across 302 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$437,797	53
2024	Research	$1,603,284	20
2023	Research	$1,873,741	21
2022	Research	$169,977	43
2021	Research	$260,513	34
2020	Research	$400,959	57
2019	Research	$335,666	74

Breakdown

Who paid Research payments · program years 2019–2025

AstraZeneca Pharmaceuticals LP $2,192,167 9 payments
E.R. Squibb & Sons, L.L.C. $729,649 25 payments
Merck Sharp & Dohme Corporation $666,901 13 payments
Pfizer Inc. $253,593 47 payments
Siemens Medical Solutions USA, Inc. $226,365 2 payments
Novartis Pharmaceuticals Corporation $219,351 7 payments
Astute Medical, Inc. $108,441 32 payments
F. Hoffmann-La Roche AG $96,956 10 payments
Endotronix, Inc. $77,901 2 payments
bioMerieux $72,060 1 payment

Studies the money was for Research payments · program years 2019–2025

PreVALOR Amendment 1 (BioVALOR) $1,150,979 2 payments
An observational study to assess the real-world effectiveness of Evusheld pre-exposure prophylaxis for prevention of COVID-19 among immunocompromised patients in the United States $1,024,540 4 payments
Phase III Adjuvant Melanoma Stage II B/C Opdivo Mono $299,508 3 payments
Safety and efficacy of anti-CD47, ALX148 in combination with liposomal doxorubicin and pembrolizumab in patients with recurrent platinum-resistant ovarian cancer# Phase II study $294,222 1 payment
STUDY NAME#Safety and efficacy of anti-CD47, ALX148 in combination with liposomal doxorubicin and pembrolizumab in patients with recurrent platinum-resistant ovarian cancer# Phase II study $274,818 1 payment
Phase I II FIH EP4 Monotherapy Combination $238,201 3 payments
Cardiac RADIoablation versus repeat catheter Ablation: a pivotal randomized clinical Trial Evaluating safety and efficacy for patients with high-risk $145,463 1 payment
A Phase II Multicenter, Open-Label, Single-Arm Dose Escalation Study of Asciminib Monotherapy in 2Nd Line Chronic Phase - Chronic Myelogenous Leukemia $126,493 2 payments
AST-132 Diamond $108,441 32 payments
Ocrelizumab in Patients With RMS $96,956 10 payments

What the money was spent on Research payments · program years 2019–2025

Overhead $32,269 13 payments
Patient care $2,117 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.